Blockchain Registration Transaction Record

BioVersys AG Shareholders Approve All Board Proposals at AGM

BioVersys AG shareholders approve all board proposals at AGM, including re-election of Chairman and election of new board member. Company advances Phase 3 trial for BV100 and Phase 2 alpibectir for MDR infections.

This news matters because BioVersys is advancing critical treatments for drug-resistant infections, a growing global health crisis. With Phase 3 trials underway for BV100 and Phase 2 for alpibectir, the company is on the frontline of developing new antibiotics against superbugs. Shareholder approval ensures continued funding and strategic direction, potentially bringing life-saving therapies to patients with limited options. For investors and healthcare professionals, this signals progress in addressing antimicrobial resistance, a top WHO priority.